Pillstats
Rx only · Capsule · Oral

Clomipramine Hydrochloride Capsules

Clomipramine Hydrochloride

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US3 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)2597
US makers1 labelers
Packages3
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.082$0.164$0.247$0.329Dec 2025Apr 2026Jul 2026
$0.233
Latest avg · Jul 22, 2026
-19%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

701392092782025 Q12025 Q22025 Q32025 Q42026 Q1
86
Rx · 2026 Q1
4.4K
Units dispensed
-64%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Lupin Pharmaceuticals,Inc.unknown3SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jun 27, 2025
    RECALLRecall (Class II): clomiPRAMINE Hydrochloride Capsules USP 25 mg, 100 count bottles, 5801 Pelican Bay Boulevard, Suite 500, Naples, Florid…

    Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention sample testing at expiry. — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide.

  • Apr 10, 2025
    RECALLRecall (Class II): clomiPRAMINE hydrochloride Capsules USP, 25 mg, 100-count bottle, Rx only, Manufactured For: Lupin Pharmaceuticals, Inc…

    Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability study. — Recalling firm: Lupin Pharmaceuticals Inc. — USA nationwide